MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$7,543,641
Unit: Dollar
Positive Cash Flow Breakdown
Stock-based compensation, includ...
Other income
Collaboration revenue
Others
Negative Cash Flow Breakdown
Prepaids and other current asset...
Deferred collaboration revenue
Accrued expenses
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
243,745
251,147
3,959,999
3,985,754
Total research and development expenses
5,030,667
4,096,580
4,940,495
11,794,054
In-process research and development
1,656
10,000
1,773,606
515,996
Total general and administrative expenses
2,255,603
3,781,977
3,269,945
8,179,521
Depreciation
2,807
2,807
6,841
6,840
Other income
408,728
433,227
325,435
1,006,772
Pre-tax loss
-
-
-21,223,018
-
Income tax benefit
-
-
3,089
-
Net loss
-6,638,260
-7,206,990
-5,708,542
-2,115,831
Depreciation
2,807
2,807
6,841
6,840
Stock-based compensation, including the issuance of restricted stock
943,911
2,195,516
1,103,628
1,070,892
Acquired in-process research and development assets
1,656
10,000
1,773,606
515,996
Prepaids and other current assets
1,218,258
-578,196
-778,712
224,625
Other assets
120,441
-
-
-
Accounts payable
58,669
-154,713
-50,580
180,358
Accrued expenses
-162,255
-1,382,199
849,207
-1,199,979
Deferred collaboration revenue
-243,745
-251,147
240,001
635,746
Net cash used in operating activities
-7,375,916
-6,208,530
-1,007,127
-1,130,603
Purchase of in-process research and development assets
1,656
885,000
648,606
515,996
Net cash used in investing activities
-1,656
-885,000
-648,606
-515,996
Proceeds from sale of common stock, net of offering costs
-41,783
10,995,387
20,348,653
-
Proceeds from the exercise of stock options
-
-
0
19,137
Payment of financing costs related to the atm offering program
124,286
-
-
-
Net cash provided by financing activities
-166,069
10,995,387
20,348,653
19,137
Net decrease in cash and cash equivalents
-7,543,641
3,901,857
18,692,920
-1,627,462
Cash and cash equivalents as of beginning of the period
50,724,643
46,822,786
28,129,866
38,339,762
Cash and cash equivalents as of end of the period
43,181,002
50,724,643
46,822,786
28,129,866
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net decrease in cash
and cash...
-$7,543,641
(12.10%↑ Y/Y)
Stock-based compensation,
including the issuance of...
$943,911
(-55.39%↓ Y/Y)
Accounts payable
$58,669
(108.93%↑ Y/Y)
Depreciation
$2,807
(-79.48%↓ Y/Y)
Acquired in-process
research and development...
$1,656
Net cash used in
operating activities
-$7,375,916
(14.25%↑ Y/Y)
Net cash provided by
financing activities
-$166,069
(-967.79%↓ Y/Y)
Net cash used in
investing activities
-$1,656
Canceled cashflow
$1,007,043
Other income
$408,728
Collaboration revenue
$243,745
Net loss
-$6,638,260
(50.47%↑ Y/Y)
Prepaids and other
current assets
$1,218,258
(153.01%↑ Y/Y)
Payment of financing
costs related to the...
$124,286
Proceeds from sale of
common stock, net of...
-$41,783
Purchase of in-process
research and development...
$1,656
Canceled cashflow
$652,473
Deferred collaboration
revenue
-$243,745
(42.17%↑ Y/Y)
Accrued expenses
-$162,255
(-111.19%↓ Y/Y)
Other assets
$120,441
Total research and
development expenses
$5,030,667
Total general and
administrative expenses
$2,255,603
Depreciation
$2,807
(-79.48%↓ Y/Y)
In-process research and
development
$1,656
Buy us a coffee
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)